RTSN · Retension Pharmaceuticals, Inc.
Price & Indicators
The closing range uses available history since Oct 9, 2026; less than a full year is stored.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RTSN
this stock
Retension Pharmaceuticals, Inc.
|
$134.81M | — | — | — | — |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 13, 2026
- This year
- 4
Retension Pharmaceuticals, Inc. closed its initial public offering on October 13, 2026, after filing its Third Amended and Restated Certificate of Incorporation with Delaware on October 9, 2026; the amended bylaws also became effective immediately before the IPO closed.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RTSN | +39.1% | — | — | — | — |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | +40.3% | — | — | — | — |